{"result": {"id": "1dd0ef33-e961-408f-8ddc-d2f18c5f346f", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>混合型高脂血症<|>EVENT<|>A condition characterized by elevated levels of both cholesterol and triglycerides requiring specific management protocols)\n##\n(\"entity\"<|>他汀类药物<|>PERSON<|>A class of cholesterol-lowering medications used as first-line treatment for hyperlipidemia)\n##\n(\"entity\"<|>PCSK9抑制剂<|>PERSON<|>A class of injectable cholesterol-lowering drugs used when statins are insufficient)\n##\n(\"entity\"<|>ω-3脂肪酸<|>PERSON<|>Prescription-grade omega-3 fatty acids used to lower triglyceride levels)\n##\n(\"entity\"<|>贝特类药物<|>PERSON<|>Fibrate medications primarily used to reduce high triglyceride levels)\n##\n(\"entity\"<|>烟酸类药物<|>PERSON<|>Niacin-based medications used for severe hypertriglyceridemia)\n##\n(\"entity\"<|>血浆分离治疗<|>EVENT<|>A therapeutic procedure for extreme cases of hypertriglyceridemia to prevent pancreatitis)\n##\n(\"relationship\"<|>混合型高脂血症<|>他汀类药物<|>Statins are the first-line treatment for mixed hyperlipidemia<|>9)\n##\n(\"relationship\"<|>混合型高脂血症<|>PCSK9抑制剂<|>PCSK9 inhibitors are used when statins fail to control LDL-C in mixed hyperlipidemia<|>7)\n##\n(\"relationship\"<|>混合型高脂血症<|>ω-3脂肪酸<|>Omega-3 fatty acids are added when triglycerides remain elevated in mixed hyperlipidemia<|>6)\n##\n(\"relationship\"<|>混合型高脂血症<|>贝特类药物<|>Fibrates are used for mixed hyperlipidemia with triglycerides >2.3 mmol/L<|>8)\n##\n(\"relationship\"<|>混合型高脂血症<|>烟酸类药物<|>Niacin may be combined with fibrates for severe mixed hyperlipidemia<|>5)\n##\n(\"relationship\"<|>混合型高脂血症<|>血浆分离治疗<|>Plasmapheresis is reserved for extreme cases of mixed hyperlipidemia with TG >5.6 mmol/L<|>4)\n##\n(\"relationship\"<|>他汀类药物<|>PCSK9抑制剂<|>PCSK9 inhibitors complement statins when LDL-C remains uncontrolled<|>7)\n##\n(\"relationship\"<|>ω-3脂肪酸<|>贝特类药物<|>Omega-3s and fibrates may be combined for triglyceride control<|>6)\n##\n(\"relationship\"<|>贝特类药物<|>烟酸类药物<|>Fibrates and niacin may be used together for severe hypertriglyceridemia<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559206, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 629, "prompt_tokens": 2813, "total_tokens": 3442, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2560}, "prompt_cache_hit_tokens": 2560, "prompt_cache_miss_tokens": 253}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 脂血症的管理流程\n基于循证医学证据和相关指南［6，22，59］，本共识\n　推荐混合型高脂血症管理流程如下：对于 TG 1.7~  5.6 mmol/L 的混合型高脂血症患者，应首先启动以  中等强度他汀类药物为基础的降胆固醇治疗方案， 并优先确保 LDL?C 达标 。若他汀类药物使用达最  大耐受剂量，LDL?C 仍未达标，则建议联合使用胆\n\n\n\n中华全科医师杂志 2024 年 9 月第 23 卷第 9 期    Chin J Gen Pract, September 2024, Vol. 23, No. 9                                  · 913 ·\n\n　固醇吸收抑制剂和/或 PCSK9抑制剂 。若 LDL?C 已 达标，而 TG仍高于 1.7 mmol/L，应考虑添加处方级 ω?3 脂肪酸；若 TG 高于 2.3 mmol/L，则可考虑使用 贝特类药物 。对于 TG 超过 5.6 mmol/L 的患者，应 立即采取措施控制 TG，以降低胰腺炎风险，可采用 贝特类药物联用处方级 ω?3 脂肪酸或烟酸类药物 的方案，必要时行血浆分离治疗 。详见图 2。\n（五）治疗监测\n　　启动药物治疗后 4~6 周复查血脂 、肝肾功能 和肌酸激酶，同时关注患者有无肌肉疼痛、乏力等 症状 。若血脂指标达标且无药物不良反应，可逐 渐延长复查间隔至每 3~6 个月 1 次 。如血脂指标 持续达标，复查频率可进一步延长至每 6~12个月 1 次 。如果启动药物治疗 1~3 个月后血脂指标未 达标，应调整降脂药物的种类或剂量，并在调整后 4~6周复查 。长期坚持使用降脂药物至关重要，不 应减少剂量或中断治疗，除非有特殊情况 。治疗 过程中若出现轻微不良反应，可在严格监测下继 续用药；若出现严重不良反应，应考虑调整剂量或\n　　　贝派地酸是一种三磷酸腺苷柠 檬酸裂解酶抑制剂，可抑制胆固醇 生物合成途径，与他汀类药物作用 机制相似 。CLEAR 研究显示贝派 地 酸 可 进 一 步 降 低 LDL?C 水 平 约 15%［60］。\n　　胆固醇酯转移蛋白（cholesteryl ester transfer protein，CETP）是 一 种  血浆糖蛋白 ，负责将胆固醇酯从  HDL?C 转 移 到 LDL?C 和 VLDL?C。 obicetrapib 作 为 新 型 选 择 性 CETP\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n注：ALT 丙氨酸氨基转移酶，AST 天冬氨酸氨基转移酶，ULN 参考值上限，CK 肌酸激酶；需注意出现严重药物不良反应者应考虑转诊 至上级医疗机构\n图3  降脂药物应用期间不良反应的处理流程\n\n\n\n· 914   ·                                                       中华全科医师�\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>中华全科医师杂志<|>ORGANIZATION<|>A medical journal publishing consensus and guidelines on hyperlipidemia management)\n##\n(\"entity\"<|>CLEAR 研究<|>EVENT<|>A study showing the effectiveness of bempedoic acid in reducing LDL-C levels)\n##\n(\"entity\"<|>贝派地酸<|>PERSON<|>An ATP citrate lyase inhibitor used to lower LDL-C levels, similar to statins)\n##\n(\"entity\"<|>胆固醇酯转移蛋白<|>PERSON<|>A plasma glycoprotein responsible for transferring cholesteryl esters from HDL-C to LDL-C and VLDL-C)\n##\n(\"entity\"<|>obicetrapib<|>PERSON<|>A novel selective CETP inhibitor)\n##\n(\"relationship\"<|>中华全科医师杂志<|>CLEAR 研究<|>The journal published findings from the CLEAR study<|>5)\n##\n(\"relationship\"<|>贝派地酸<|>CLEAR 研究<|>The CLEAR study demonstrated the efficacy of bempedoic acid<|>8)\n##\n(\"relationship\"<|>胆固醇酯转移蛋白<|>obicetrapib<|>obicetrapib is a selective inhibitor of CETP<|>7)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_fc97b191c8caf282d716b0a0e9ca1506fc59bb518c54cbce1b3ba24cf11ad954_v2"}